⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PHAT News
Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
globenewswire.com
PHAT
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
globenewswire.com
PHAT
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
PHAT
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
PHAT
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
PHAT
Shaya Prager Announces Opal Holdings Leasing Activity of 250,000 Square Feet Across Portfolio in 2025
prnewswire.com
SBUX
BAC
CI
MS
DRS
PHAT
Philatron Expands U.S. Manufacturing Capacity to Support the Surging Demand for High-Performance Data Center Cabling & A.I. Infrastructure
prnewswire.com
PHAT
NTC, con el respaldo de Wise Equity, completa la adquisición del negocio de oftalmología de Pharmathen USA - español USA - Deutsch USA - Français Italia - Italiano USA - English
prnewswire.com
PHAT
NTC, UNTERSTÜTZT VON WISE EQUITY, SCHLIESST DIE ÜBERNAHME DES OPHTHALMOLOGIE-GESCHÄFTS VON PHARMATHEN AB USA - Deutsch Italia - Italiano USA - Français USA - español USA - English
prnewswire.com
PHAT
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
globenewswire.com
PHAT